NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
Clinical Trials
9 trialsNCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT00421525 2021-08-16
Phase I/II Study of hLL1 in Multiple Myeloma
Gilead Sciences
Phase 1/2 Completed
NCT04665076 2020-12-11
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT00821249 2020-10-19
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Pfizer
Phase 1/2 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT00911105 2018-06-06
REVLIMID-NIS
iOMEDICO AG
Completed
NCT02303353 2017-02-24
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
SPGO Research Mannheim GmbH
Unknown
NCT01199718 2011-06-15
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Cylene Pharmaceuticals
Phase 1 Unknown